AstraZeneca blocks Advent's $7.6-bn buyout of Swedish Orphan Biovitrum
The UK drugmaker's opposition meant the offer fell short of the 90 per cent threshold needed for approval
 "AstraZeneca blocks Advent's $7.6-bn buyout of Swedish Orphan Biovitrum")
premium
AstraZeneca effectively blocked a $7.6 billion takeover of Swedish Orphan Biovitrum (Sobi) by withholding its 8% stake in the drugmaker from a buyout offer by Advent International and Singapore wealth fund GIC, according to people familiar with the situation.
The UK drugmaker’s opposition meant the offer fell short of the 90 per cent threshold needed for approval, torpedoing what would have been the largest take-private deal in European health care sector this year.
Sobi lost a quarter of its value.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%